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Abstract
MAb 4C5 is a cell impermeable, anti-HSP90 murine monoclonal antibody, originally produced using hybridoma technology.
We have previously shown that mAb 4C5 specifically recognizes both the a- and to a lesser extent the b-isoform of HSP90.
Additionally, in vitro and in vivo studies revealed that by selectively inhibiting the function of cell-surface HSP90, mAb 4C5
significantly impairs cancer cell invasion and metastasis. Here we describe the reconstitution of mAb 4C5 into a mouse-
human chimera. More importantly we report that mAb 4C5 and consequently its chimeric counterpart are completely
devoid of heavy chain and consist only of a functional kappa light chain dimer. The chimeric antibody is shown to retain the
original antibody’s specificity and functional properties. Thus it is capable of inhibiting the function of surface HSP90,
leading to reduced cancer cell invasion in vitro. Finally, we present in vivo evidence showing that the chimeric 4C5
significantly inhibits the metastatic deposit formation of MDA-MB-453 cells into the lungs of SCID mice. These data suggest
that a chimeric kappa light chain antibody could be potentially used as an anti-cancer agent, thereby introducing a novel
type of antibody fragment, with reduced possible adverse immunogenic effects, into cancer therapeutics.
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Introduction
Heat shock protein 90 (HSP90) is considered a very attractive
drug-target for cancer therapy, since most of its client proteins
play key roles in the acquisition and/or maintenance of the
malignant phenotype [1–4]. Recently, we and others have
identified a pool of HSP90 at the cell surface [5–8], where it was
shown to participate in cancer cell invasion and metastasis [9–
11]. Increasing evidence continues to reinforce the notion of a
wide-ranging phenomenon of extracellular HSP90 chaperoning,
implicated in cancer progression and metastatic spread [12–16]
thus supporting the development of inhibitors that specifically
target the cell surface HSP90. MAb 4C5 is a cell-impermeable
murine monoclonal antibody produced using hybridoma
technology [17], that specifically recognizes both the a and to
al e s s e re x t e n tt h eb isoform of HSP90 [8]. MAb 4C5 was
initially shown to inhibit cell migration processes in vitro during
development of the nervous system [18,19] by affecting actin
cytoskeletal re-arrangement and formation of motile structures
such as lamellipodia [8,20]. Subsequently evidence was
presented showing that by binding selectively to the surface
pool of HSP90, mAb 4C5 significantly reduces melanoma cell
invasion and metastasis [11]. Furthermore mAb 4C5 was shown
to inhibit the extracellular interaction between HSP90 and the
growth factor receptor ErbB-2 in MDA-MB-453 breast cancer
cells, leading to impaired downstream signalling and reduced
cancer cell motility and invasion [21]. Finally, mAb 4C5 was
shown to inhibit a functional interaction between secreted
HSP90 and the inactive forms of metalloproteinases 2 and 9,
necessary for the enzymes’ activation which is essential for
cancer cell invasion and extravasation [14]. These combined
data suggested that the unique capacity of mAb 4C5 to
specifically inhibit the extracellular pool of HSP90 without
affecting the wide range of important intracellular roles of this
chaperone could have clinical benefits in the treatment of
human malignancies. However, murine mAbs do not constitute
ideal therapeutic agents, since their potential immunogenicity
represents a limitation to their clinical use. The application of
mouse mAbs to human therapy has become feasible by the
advent of recombinant DNA technologies which has led to the
development of chimeric and humanized antibodies which
exhibit reduced immunogenicity [22] without a significant loss
in the affinity, especially in the case of chimeric antibodies
[23,24].
In the current work we describe the cloning and sequencing of
the mAb 4C5 genes from the originating hybridoma cell line and
the successful construction of a functional mouse-human chimera,
which is shown to retain the properties of the parental antibody.
More importantly we report that mAb 4C5 is completely devoid of
heavy (H)-chain and consists of only a functional immunoglobulin
kappa light chain dimer and its properties can be recapitulated in a
recombinant protein containing only this light (L)-chain polypep-
tide. Finally, we demonstrate the potential therapeutic efficacy of
this novel type of antibody fragment.
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MAb 4C5 is an antibody fragment completely devoid of a
heavy chain
The electrophoretic motility of mAb 4C5 studied under reducing
and non-reducing SDS-PAGE revealed that it is not a conventional
IgG molecule. More specifically, when purified mAb 4C5 was
subjected to reducing SDS-PAGE, followed by immunoblotting
withananti-Fab, wedidnot observe thetypical 25 kDaand 50 kDa
bands corresponding to the L- and H-chain, respectively of a
conventional IgG antibody, but instead a single band at
approximately 25 kDa (Fig. 1A). Interestingly an identical 25 kDa
band was obtained after immunoblotting with an anti-kappa L-
chain antibody (Fig. 1A). Accordingly, after non-reducing electro-
phoresis immunoblotting with both of these standard-antibodies,
shows mAb 4C5 to be significantly smaller than a conventional
IgG1 molecule sinceitmigrated atapproximately50 kDa.(Fig. 1A).
Finally, no immunoreactivity was detected after electrophoresis of
mAb 4C5 under both reducing and non-reducing conditions,
followed by immunoblotting using an anti-Fcc (Fig. 1A). These
combined data indicated that mAb 4C5 may either lack a part of its
H-chain, or that it is completely devoid of H-chain. In order to
further explore these possibilities we next performed northern blot
analysis using an IgG1 H-chain probe. RNA derived from
hybridoma cells that produce an intact IgG1 immunoglobulin
named 2D10 served as positive control. In contrast to the positive
control, no radioactivity was detected after hybridization of the
RNAs derived from the mAb 4C5 hybridoma and NSO myeloma
cells (negative control) (Fig. 1B), indicating that mAb 4C5 may
completely lack a H-chain gene. This was further confirmed by H-
chain PCR amplification experiments. For the amplification of the
H-chain cDNA of mAb 4C5, a panel of eight mouse universal
primersand a polyA+ primerrespectivelydirected against the 59and
the 39 ends of the mRNA, were tested in several separate PCR
reactions. In all conditions tested no amplification of a specific H-
chain product was observed (data not shown). These combined data
suggested that mAb 4C5 is devoid of H-chain and we therefore
proceeded to the recombinant expression of the antibody L-chain
alone in order to explore its properties.
Construction of the chimeric L- chain antibody
The initial amplification of the mAb 4C5 kappa chain gene
from the first strand cDNA template was performed using
universal mouse L-chain primers according to Barbas [25]. The
PCR product corresponding to the full length mab 4C5 L-chain,
was then subcloned into the pComb3H vector. Sequence analysis
of recombinant L-chain (rec-4C5) revealed that it belongs to the
kappa chain subgroup I [26] (Fig. 2).
Chimeric L-chain antibody (ch-4C5) was constructed by
replacing the mouse LCk coding region with the corresponding
human LCk insert. The sequence analysis of several recombinant
clones confirmed the successful construction of the chimeric
mouse-human antibody.
Both rec-4C5 and ch-4C5 were expressed in the bacterial
periplasmic space and purified as described in Materials and
Methods. The electrophoretic motilities of the purified antibodies
were tested under reducing and non-reducing conditions and were
found to be similar to the corresponding motility of the original
mAb 4C5 antibody (Fig. 3A).
ch-4C5 specifically recognizes HSP90
In order to explore the specificity of the antibodies, western blot
analysis was performed in MDA-MB-453 breast cancer cell lysates
using a commercial polyclonal anti-HSP90a antibody (Chemicon
International, USA), mAb 4C5, rec-4C5 and ch-4C5. In all cases a
single identical immunoreactive band was observed (Fig. 3B),
confirming that both rec-4C5 and ch-4C5 retain the specificity of
the paternal mAb 4C5. This result was further confirmed by
immunoprecipitation experiments performed in pre-cleared
MDA-MB-453 cell lysates using anti-HSP90a, followed by
immunoblotting with mAb 4C5, rec-4C5 or ch-4C5. In all cases,
a single immunoreactive band was observed, indicating that the
chimeric L-chain specifically recognize HSP90 (Fig. 3C). The
same result was obtained when immunoprecipitation was
performed using mAb 4C5, rec-4C5 and ch-4C5 followed by
western blot with the anti-HSP90a antibody (Fig. 3D). In all
experiments an irrelevant mouse IgG was used as negative control.
ch-4C5 is cell-impermeable and does not affect the
function of intracellular HSP90
In order to investigate whether ch-4C5 binds to surface HSP90,
unfixed MDA-MB-453 cells were incubated with either rec-4C5 or
ch-4C5 while in culture. Thus, the antibodies had access only to
the external surface of the cells. Following incubation, cells were
processed for indirect immunofluoresence using a fluorescently-
labelled secondary antibody. The observed typical punctuate
immunostaining confirmed the cell surface labeling (Fig. 4A).
Similar results were obtained when using anti-HSP90a and mAb
4C5 (Fig. 4A). It is noteworthy that similarly to mAb 4C5, ch-4C5
as well as rec-4C5 also recognize the intracellular pool of HSP90
as demonstrated by immunofluoresence after fixation and
permeabilization of MDA-MB-453 cells (Fig. 4B). Finally, the
binding of antibodies to live MDA-MB-453 cells was monitored at
various time intervals. As shown in Fig. 4C, similarly to mAb 4C5,
rec-4C5 and ch-4C5 were not internalized and remained bound
on the cell surface for up to 24 h in culture.
The significance of ch-4C5 cell-impermeability was investigated
by monitoring the levels of a subset of intracellular HSP90 client
proteins. To date more than 100 intracellular HSP90 client proteins
have been identified. Cell-permeable HSP90 inhibitors induce the
degradation of these proteins because their stability depends on
intracellular HSP90 function [3]. Since our data suggested that
mAb 4C5 and subsequently rec-4C5 and ch-4C5 are cell
impermeable, we examined their ability to impact the stability of
three well-characterized HSP90 client proteins, Akt, cRaf and
ErbB-2. Following incubation of MDA-MB-453 cells with different
concentrations of mAb 4C5, rec-4C5 and ch-4C5, the levels of Akt,
cRaf and ErbB2 were monitored by western blotting. As shown in
Figure 4D these antibodies did not affect the steady-state levels of
any of the kinases studied. In contrast when the cells were incubated
with the cell permeable anti-HSP90a, expression levels of these
kinases were significantly reduced (Fig. 4D).
ch-4C5 inhibits cancer cell invasion
Previous studies have shown that mAb 4C5 inhibits MDA-MB-
453 breast cancer and B16 F10 melanoma cell invasion in a wound
healing assay [11,21]. In order to confirm that ch-4C5 exhibits the
same functional property, we performed in vitro wound healing
assays using MDA-MB-453 and B16 F10 cancer cells. Control
cultures were grown either in culture medium alone, or in culture
medium containing 200 mg/ml of the irrelevant BM88 antibody.
No statistically significant difference was observed between the two
types of controls used. The mean value of the two types of control
was considered as 100% of wound closure. As shown in Fig. 5A,B
the presence of ch-4C5 in the culture medium significantly reduced
the extend of MDA-MB-453 cancer cell invasion within the
migration gap after 24 h, as compared to control cultures. More
specifically, the presence of ch-4C5 resulted in a 46% inhibition of
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HSP90a, as well as mAb 4C5 and rec-4C5 were included in the
culture medium (Fig. 5A,B). The bars in Fig. 5B represent the
average of three independent experiments 6SEM. Within a single
experiment, each condition was tested in triplicate. Similar results
were obtained using B16 F10 melanoma cells and increasing
concentrationsofch-4C5whichyieldeda dosedependentinhibition
of cell invasion (Fig. 5C,D). It is important to note that in the wound
healing assay the effect of ch-4C5 is directed towards cell invasion
and not cell proliferation as judged by an independent MTT assay
(data not shown). This is in accordance with previously published
data demonstrating that the presence of mAb 4C5 in the culture
medium of B16 F10 [11] and MDA-MB-453 [21], does not affect
cell proliferation, since low BrdU incorporation was observed with
no apparent differences in the absence or presence of the antibody.
At this point it should be noted that the inhibitory effect of the
anti-HSP90a antibody on the MDA-MB-453 invasion rate was in
great part due to increased cell death as judged by trypan blue
staining, which selectively colours dead cells (Fig. 5E). In contrast,
when cultures were treated with mAb 4C5 and ch-4C5, the
incidence of cell death was similar to that observed in the control
cultures (Fig. 5E). This result further supports that ch-4C5, in
contrast to the cell-permeable anti-HSP90a antibody, is cell-
impermeable and does not affect the intracellular pool of HSP90,
which is important for cell survival.
Finally these cultures were examined with respect to actin re-
arrangement dynamics using fluorescently labelled phalloidin.
MDA-MB-453 cells exposed to ch-4C5 were less spread compared
to cells in control cultures, and their morphology was indicative of
non-motile cells. Furthermore, when visualized at a higher
magnification, the lamellipodia in treated cultures were less
developed and less spread out compared to lamellipodia in control
cultures (Fig. 5 F,G). These results are in accordance with
previously published data regarding the effect of mAb 4C5 on
actin re-arrangement and lamellipodia development [21].
ch-4C5 reduces the MDA-MB-453 metastatic deposition
into the lungs of SCID mice
We next sought to investigate the in vivo effect of ch-4C5 on the
metastatic behaviour of MDA-MB-453 cancer cells. For this
purpose, MDA-MB-453 cells were pre-treated or not with
200 mg/ml ch-4C5 and then labelled with the fluorescent dye
DiO and injected intravenously into SCID mice via the tail vein.
Twelve hours after the injection, mice were euthanized and the
metastatic deposits of MDA-MB-453 cells were traced and
evaluated in the lungs of both the control and the ch-4C5-treated
groups. As shown in Fig. 6A, a significant decrease in the
deposition of MDA-MB-453 cells was detected in the ch-4C5
treated mice as compared to the control animals. More
specifically, quantification of the metastatic deposit formation
showed a 38% inhibition in the ch-4C5 treated mice when
compared to control mice (Fig. 6B).
Discussion
In this study, we describe the cloning and sequencing of an anti-
HSP90 murine monoclonal antibody, named mAb 4C5. More
importantly, we demonstrate that mAb 4C5 is not a conventional
Figure 1. mAb 4C5 is a kappa L- chain dimer. A. Electrophoretic analysis of mAb 4C5, followed by immunoblotting with an anti-mouse kappa
chain,ananti-mouse Fab andananti-Fccantibody.Intact IgG1 immunoglobulinproducedbythe2D10 hybridomacellsservesaspositivecontrol.Under
reducing electrophoresis followed by westernblot with the anti-Fab antibody, a single 25 kDa-immunoreactive band is observed, instead of the 25- and
50-kDa bands corresponding to the L- and H-chain, respectively, of an intact IgG1. This 25 kDa band is identical to the band corresponding to the kappa
L-chain as shown by western blot with the anti-mouse kappa chain antibody. Under-non reducing electrophoresis followed by western blot with both
the anti-kappa and the anti-Fab antibodies, mAb 4C5 is shown to migrate at approximately 50 kDa, and not at 150 kDa as expected for an intact IgG1
molecule. No mAb 4C5 immunoreactivity is detected after electrophoresis under both reducing and non-reducing conditions followed by western blot
with an anti-Fcc antibody.In the case of the IgG1 immunoglobulin under the same conditions a 50 kDa anda 150 kDa band is observed, respectively. B.
No radioactivity is detected after northern blot analysis of 4C5 hybridoma-derived RNA with a H-chain radiolabelled probe. RNA derived from the IgG1-
producing 2D10 hybridoma cells and the NSO myeloma cells served as positive and negative control, respectively.
doi:10.1371/journal.pone.0023906.g001
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only consists of a kappa light chain dimer. This finding was
initially supported by SDS-PAGE electrophoresis under denatur-
ing and non-denaturing conditions, demonstrating that mAb 4C5
migrates unconventionally at approximately 26- and 50-kDa,
respectively. Additionally, when total RNA isolated from the mAb
4C5-producing hybridoma cell line was subjected to northern blot
hybridization using an IgG1 H-chain cDNA radio-labeled probe,
no radioactivity could be detected. In agreement with the above
results, when we attempted to amplify the H-chain cDNA using
universal mouse H-chain primers we could not isolate a H-chain
product in all conditions tested. Finally, the unusual nature of
mAb 4C5 was confirmed beyond any doubt, since the recombi-
nant kappa L-chain expressed in bacteria was shown to retain all
the properties of the paternal antibody, including antigen binding
and in vitro inhibition of cancer cell invasion.
This monoclonal antibody was originally produced by immu-
nization of mice with a brain-derived membrane fraction of 15
day-old rat embryos [17], and it was shown to specifically
recognize and inhibit the function of surface HSP90 during cell
migration processes [8]. Additionally, mAb 4C5 was shown to
significantly reduce the rate of invasion and metastasis of cancer
cells. More specifically, it was demonstrated that this antibody
inhibits melanoma cell invasion and metastasis [11] as well as the
interaction of surface HSP90 with the extracellular domain of
ErbB-2, leading to impaired downstream signalling and subse-
quently reduced rate of in vitro breast cancer cell invasion [21].
Even more recently, Stellas et al. [14] provided in vitro and in vivo
evidence showing that mAb 4C5 indirectly inhibits the activation
of pro-gelatinases MMP-2 and MMP-9, necessary for cancer cell
invasion, extravasation and metastasis. These combined data
further supported the idea that mAb 4C5 could be useful as a
cancer therapeutic and oriented our studies towards the
determination of the aminoacid sequence and recombinant
expression of this antibody.
It is well known that murine antibodies have limited use for in
vivo therapy in humans because of their immunogenicity. In
multiple instances this problem has been overcome using genetic
engineering approaches to produce chimeric mouse-human and
fully humanized antibodies. Taking into consideration the
unconventional nature of mAb 4C5 in combination with the fact
that during the humanization process the antibody affinity is
frequently reduced, we next reconstituted the murine mAb 4C5
into a functional mouse-human chimeric version that, like the
paternal antibody, binds to surface HSP90, is cell impermeable
and inhibits cancer cell invasion. The chimeric antibody which
was engineered by replacing the Ck- region of the paternal murine
antibody with the corresponding human Ck-region was shown to
retain the specificity and affinity of the paternal mouse antibody.
It has been a generally accepted concept that the antibody
molecule requires both the H- and L-chains for its full activity
[27]. Moreover, the H-chain is believed to be the predominant
contributor to the free energy of antigen binding while the
contribution of the L-chain is supposed to be limited [28,29]. The
latter idea is further supported by the fact that cameloids possesses
a class of fully functional antibodies completely lacking L-chains
and consisting of H-chain dimers [30,31]. In context to these
findings, H-chains alone were shown to interact with a variety of
antigens in a specific manner (albeit with lower affinity than the
intact antibodies), which has led to the application of single
domain antibodies derived from the H-chains [32] in research,
biotechnology as well as human therapeutics. In the past, there
have been sporadic reports of antigen binding by L-chains. The
first examples of free inmmunoglobulin light chains concerned the
Figure 2. Nucleotide and aminoacid sequences of mAb 4C5. Nucleotide and amino acid sequences of the L-chain variable region of mAb 4C5.
doi:10.1371/journal.pone.0023906.g002
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dimers expressed by multiple myeloma cells, collected from the
urine of human patients [33]. Furthermore, large amounts of L-
chains were found to accumulate in the extracellular fluids and
tissues of patients with L-chain secreting tumors [34]. A kappa
light chain dimer with CD4 antigen specificity derived from a
hybridoma cell line was described in 1987 by Ledbetter et al. [35]
and in 1994 Mei Sun et al [36] reported that a purified L-
chain from a monoclonal antibody against vasoactive intestinal
polypeptide (VIP) displayed sequence-specific and high affinity
binding to VIP. Accordingly, Nishimura et al. [37] reported the
production of a recombinant l light chain exhibiting a
significantly higher activity of binding to the antigen compared
with the intact antibody. Furthermore, these authors presented
evidence that this recombinant light chain could serve as a
potentially useful vehicle for clinical use such as radio-immunoi-
maging and radio-immunotherapy of lung cancers. It has been
also reported that antibody L-chain dimers produced by a mouse
hybridoma react with human melanoma tissues [38]. In 1998
Pereira et al. [39] showed that a single L-chain variable sequence
contains all the determinants necessary for cardiolipin binding,
with an affinity similar to that of the intact antibody. More
recently, Dubnovitsky et al. [40] reported that the recombinant
VL-domain of a monoclonal antibody against ferritin preserved its
antigen binding function with an affinity comparable to that of the
full-length parental antibody.
In the present work we have demonstrated that ch-4C5 is
completely devoid of a heavy chain and consists of a L-chain
dimer. ch-4C5 has a high specific activity as demonstrated by
immunoblotting and immunofluoresence experiments using breast
cancer cells. Furthermore and similarly to the paternal antibody
ch-4C5 exhibits function-blocking properties as judged by the
in vitro wound healing assay. Finally, using an in vivo assay we have
demonstrated that ch-4C5 reduces the metastatic deposition of
MDA-MB-453 breast cancer cells into the lungs of SCID mice.
These results provide a new perspective for the clinical
application of L-chain antibodies in cancer therapeutics. Recom-
binant L-chain antibodies have a number of advantages over
intact antibodies and VH antibodies when intended for human
therapeutics, i.e relatively facile and reproducible production,
quality control procedures, and faster clearance from the
circulation. Finally from a clinical point of view, surface HSP90
provides a novel and very promising extracellular drug target for
the effective treatment of metastatic cancer. In this context, the
ability of ch-4C5 to selectively inhibit the function of the surface
pool of HSP90, as indicated by the in vitro and in vivo data
presented in the current work, without interfering with HSP90
intracellular function, renders this antibody fragment a potential
cancer therapeutic.
Materials and Methods
Ethics Statement
All animal studies were conducted according to the national and
international guidelines and were specifically approved by the
Ethical Committee of the Hellenic Pasteur Institute (Permit No:
K/533, Veterinary Directorate District of Attiki). SCID mice were
originally purchased from Jackson Laboratory, bred and main-
tained under specific pathogen free conditions at the Experimental
Animal Unit of the Hellenic Pasteur Institute. All of the
experiments with animals were performed in accordance with
the guidelines approved by the Ethical Committee of the Hellenic
Pasteur Institute.
RNA and DNA manipulations
Total RNA was isolated from 10
7 hybridoma cells [17], using
the ‘Absolutely RNA Mini Prep kit’ (Stratagene). For Northern
blot analysis, 25 ug RNA was separated by agarose electropho-
resis, transferred to Zeta-Probe (Biorad) and hybridized with a 1.2-
kb H-chain IgG1a cDNA probe as previously described [41]. For
amplification of the VH and VL antibody fragments, specific first
strand cDNAs were synthesized using the ‘1
st Strand cDNA
Synthesis kit for RT-PCR’ (Roche), according to the manufactur-
er’s instructions. The cDNAs were subsequently amplified by
PCR, using specific mouse immunoglobulin primers [25]. The
amplified L-chain cDNA fragment was inserted into the SacI/
XbaI restriction sites of the pComb3H phagemid (generous gift of
Drs. C. F. Barbas and D. R. Burton, The Scripps Research
Institute, La Jolla, CA) [25] and sequenced in both directions at
the sequence facility of the Institute of Molecular Biology and
Biotechnology (IMBB). The germline counterpart of the rear-
Figure 3. Electrophoretic mobility and specificity of antibodies.
A. Left panel: SDS-PAGE of purified antibodies under reducing
conditions followed by Coomasie Brilliant Blue-R staining revealed in
all cases an approximately 25 kDa band corresponding to the L-chain.
Right panel: Under non-reducing conditions the antibodies are shown
to migrate as a L-chain dimer. B. Western blot of MDA-MB-453 cell
lysates using mAb 4C5, rec-4C5, ch-4C5 and a commercial anti-HSP90a
antibody, serving as positive control. In all cases a single 90 kDa
immunoreactive band corresponding to HSP90 is observed.
C. Immunoprecipitation in MDA-MB-453 cell lysates with anti-HSP90a,
followed by immunoblotting with either the murine or the recombinant
antibodies. In all cases a single immunoreactive band is observed.
D. Reverse immunoprecipitation experiments in MDA-MB-453 cell
lysates using mAb 4C5, rec-4C5 and ch-4C5, followed by western blot
with anti-HSP90a. In all cases a single immunoreactive band is observed
indicating that both recombinant antibodies recognize HSP90.
doi:10.1371/journal.pone.0023906.g003
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Biotechnology Information IgBLAST server (http://www.ncbi.
nlm.nih.gov/igblast/) and sequence was aligned using ClustalW
software.
Construction of mouse-human ch-4C5
The mouse-human chimeric antibody was constructed by fusing
the mAb 4C5 VL cDNA to a human Ck gene segment. Briefly, the
kappa light chain of mAb 4C5 was subcloned into pBluescript SK-
plasmid, and then the BsgI/XbaI fragment containing the mouse
Ck region was replaced by the BsgI/XbaI restriction fragment
containing the human Ck. Finally, the chimeric kappa L-chain
gene was inserted into the SacI/XbaI sites of pComb3H. All DNA
manipulations were performed according to Sambrook [42].
Expression, purification and electrophoretic analysis of
recombinant L-chains
Soluble recombinant antibody L-chains were produced from
individual bacterial colonies as described previously [25] and the
periplasmic fractions were extracted according to Charlton [43]
and purified by affinity chromatography using a KappaSelect
column (GE Healthcare) on an FPLC AKTA system (Amersham
Figure 4. ch-4C5 binds to the surface pool of HSP90 and is not internalized by MDA-MB-453 cells. A. Immunofluoresence labelling of
MDA-MB-453 cells using both the rec-4C5 and ch-4C5. The punctuate immunolabeling indicates the surface pool of HSP90. Negative controls were
performed using an antibody against the intracellular protein b tubulin (data non shown). Scale bar: 20 mm B. Immunofluoresence detection of
intracellular HSP90 in fixed MDA-MB-453 cells, permeabilized with 0.1% Triton X-100. Similarly to the murine antibody, rec-4C5 and ch-4C5 recognize
the intracellular pool of HSP90. Scale bar: 20 mm C. For detection of antibody internalization, live cells were incubated with the antibodies for various
time intervals, then fixed, permeabilized and fluorescently labelled. No internalization of mAb4C5, rec-4C5 and ch-4C5 is observed even after 24 h of
incubation. In contrast the anti-HSP90a antibody could be detected intracellularly after 24 h of incubation. Scale bar: 20 mm D. MDA-MB-453 cell
lysates, treated with mAb 4C5, rec-4C5, ch-4C5 and anti-HSP90a were analyzed by western blot using antibodies against ErbB2, Akt, cRaf and HSP90a.
Actin served as a loading control. Presence of mAb 4C5, rec-4C5 and ch-4C5 did not affect the levels of the kinases compared to controls. In contrast
the cell permeable anti-HSP90a antibody significantly reduced the levels of ErbB2, Akt and cRaf.
doi:10.1371/journal.pone.0023906.g004
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instructions. The electrophoretic motilities of antibodies were
analyzed under reducing and non-reducing conditions and
visualized either with Coomassie Brilliant Blue-R stain or by
immunoblot using specific secondary HRP-conjugated antibodies.
Preparation of cell lysates, immunoprecipitation and
western blot analysis
MDA-MB-453celllysateswereobtained,quantifiedandprocessed
for immunoprecipitation as previously described [21]. Bound
proteins were analyzed by gel electrophoresis followed by western
blot and antibody complexes were detected using DAB (Sigma) or/
and an ECL chemiluminescence reagent (Amersham), as described
by the manufacturers. For all immunoprecipitation experiments,
negative controls were performed using irrelevant IgGs.
Cell cultures and immunofluorescence
MDA-MB-453 breast cancer (ATCC Cell Biology Collection)
and B16 F10 melanoma (ATCC Cell Biology Collection) cell lines
were maintained in RPMI and DMEM, respectively supplement-
ed with 10% fetal bovine serum (FBS). For immunofluorescence
studies, MDA-MB-453 cells were plated on poly-L-lysine coated
coverslips at a density of 5610
4 cells/well in 48-well plates, fixed
and processed as previously described [17]. Live MDA-MB-453
cells were labelled by indirect immunofluorescence as previously
reported [8]. Alexa546-labeled phalloidin (Molecular Probes,
Eugene, OR) was used to visualize F-actin. For all experiments,
controls were performed by omitting the primary antibodies or by
using an IgG2a mAb against the unrelated neuronal protein
BM88 [44]. Immunofluorescence was analyzed by confocal
microscopy using a Leica TSC confocal microscope.
Figure 5. ch-4C5 inhibis cancer cell invasion in vitro.A . Wound healing assay. Photographs represent phase-contrast images obtained at zero
time (left panel) and at 24 h (right panel) after scratch formation, showing MDA-MB-453 cell migration either in control cultures or cultures including
anti-HSP90a, mAb 4C5, rec-4C5 or ch-4C5. Scale bar: 200 mm. B. Quantitative effect of antibodies on the closure of the wound. Addition of 200 mg/ml
of anti-HSP90a and mAb 4C5 in the culture medium resulted in a 48% and 55% reduction of wound closure, respectively when compared to control
cultures that were considered as resulting in 100% wound closure. Addition of 200 mg/ml rec-4C5 and ch-4C5 in the culture medium resulted in a
46% and 46% inhibition of wound closure, respectively. Statistical significance of differences was assessed by Student’s t test. The presence of anti-
HSP90a, mAb 4C5, rec-4C5 or ch-4C5 had a statistically significant effect on the wound closure (p,0.01 in each case). C. Phase-contrast images
obtained at zero time (left panel) and at 24 h after scratch formation (right panel), showing B16 F10 melanoma cell invasion in a wound healing assay
in the presence of 200 mg/ml of ch-4C5. Scale bar: 200 mm. D. Quantitative effect of increasing concentrations of ch-4C5 on the invasion level of B16
F10 melanoma cells. Presence of 50 mg/ml ch-4C5 resulted in 15% inhibition of invasion, while addition of 100 mg/ml and 200 mg/ml ch 4C5 resulted
in 21% and 43% inhibition of migration, respectively when compared to control cultures that were considered as resulting in 100% wound closure.
E. Visualization of dead cells using trypan blue dye. In ch-4C5 treated cultures, the cell death incidence is similar to that observed in the control
cultures. In contrast, in the cultures treated with the anti-HSP90a antibody, a much greater number of cells are stained with Trypan blue, indicating
an increased incidence of cell death Scale bar, 30 mm. F. Control and ch-4C5 treated cells were fixed permeabilized and stained with fluorescently
labelled phalloidin. Scale bar 40 mm G. Higher magnification showing phalloidin staining (F-actin). Ch-4C5 effectively blocks spreading of
lamellipodia. Scale bar: 16 mm.
doi:10.1371/journal.pone.0023906.g005
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incubated with the antibodies while in culture for various time
intervals. The cells were then washed and fixed. For detection of
possible internalization of the antibody, cells were permeabilized
with 0.1% Triton X-100 and subsequently incubated with
Alexa488-conjugated secondary antibody (Molecular Probes,
Eugene, OR). For all experiments, controls were performed as
described above.
Wound healing assay
The assay was performed as previously described [21]. Briefly,
MDA-MB-453 and B16 F10 cells were plated in 48-well plates at a
density of 1610
5 and 2.5610
5 cells/well, respectively. After 24 h
the medium was changed to serum free and 16 h later a cell free
area was generated by scratching the cell monolayer with a sterile
yellow pipette tip, thus resulting in the formation of an
approximately 1 mm-wide cell-free area. Immediately after
scratching, the medium was replaced with fresh, containing anti-
HSP90a, mAb 4C5, rec-4C5 or ch-4C5. All agents were
maintained in the culture for the duration of the assay. Control
cultures were grown either in culture medium alone or in culture
medium containing the BM88 antibody. Migration of cancer cells
within the gap was monitored microscopically at given time
intervals, using a Leica DM IL inverted microscope, equipped
with a LEICA DM300 video camera. Migration distance was
estimated by acquiring and analyzing digital images, using Image
Pro Plus analysis software. Wound closure in the control cultures
was considered as 100% and wound closure in the antibody
treated cultures was estimated proportionally compared to the
control cultures. Statistical analysis was performed using Student’s
t-test.
Trypan blue staining
At the end point of the wound-healing assay, MDA-MB-453
cells were incubated for 5 min with 0.4% trypan blue in PBS,
washed and visualized using a Leica microscope.
MDA-MB-453 cell metastatic deposit formation in the
lung
The in vivo metastatic deposit formation assay was performed as
previously described [14,45]. Briefly, MDA-MB-453 cells were
pre-incubated with either 200 mg/ml ch-4C5 or the unrelated
BM88 antibody for 2 hours, washed and incubated with DiO for
an additional 1 hour. Cells were then washed again, trypsinized
and counted. Twenty 8–10-week-old female SCID mice were
divided into two equal groups: the control group injected with
non-treated cells or BM88- treated cells and the ch-4C5 treated
group The animals were euthanized 12 hours later and their lungs
Figure 6. ch-4C5 inhibits the metastatic deposition of MDA-MB-453 cancer cells into the lungs of SCID mice. Control or ch-4C5 treated
MDA-MB-453 cells were labeled with the fluorescent dye DiO and injected into SCID mice as described in Materials and Methods. Evaluation of
metastatic deposits was performed several hours later. A. Representative cryosections of the lungs of control and ch-4C5 treated mice. The arrows
show MDA-MB-453 cells stained with DiO present in the lung tissue. A significant decrease in the deposition of cancer cells was observed in the lungs
of ch-4C5 treated mice. Scale bar: 100 mm B. Quantitative effect of ch-4C5 on the metastatic deposition of MDA-MB-453 cells into the lungs, showed a
38% inhibition when compared to control animals. The bars represent the average of two independent experiments 6SEM. Statistical significance of
differences was tested by Student’s t test (p,0.01).
doi:10.1371/journal.pone.0023906.g006
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200 ml of saline buffer with the use of a peristaltic pump
connected to the left ventricle of the heart. This procedure ensures
that all cancer cells which are not attached, either on the inner
surface of the blood vessels or on the lung tissue, are removed.
Finally the lungs were perfused with 4% formalin solution and
then embedded in OCT solution and processed for sectioning.
Each cryosection was counter stained with TOPRO-3 and
visualised using a confocal microscope. The same experiment
was performed twice with similar results. Statistical analysis was
performed using the Student’s t-test.
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